$EVOK
Evoke Pharma Inc

2014 Q3 Form 10-Q Financial Statement

#000119312514308400 Filed on August 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $730.0K $620.0K $70.00K
YoY Change 78.05% 785.71% -53.33%
% of Gross Profit
Research & Development $3.088M $2.875M $130.8K
YoY Change 3822.69% 2097.22% -38.57%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.821M $3.492M $203.4K
YoY Change 686.91% 1616.55% -4.5%
Operating Profit -$3.821M -$3.492M -$203.4K
YoY Change 686.91% 1616.55%
Interest Expense $5.906K -$60.00K -$40.00K
YoY Change -114.77% 50.0%
% of Operating Profit
Other Income/Expense, Net -$4.181K -$55.18K -$36.45K
YoY Change 1244.37% 51.38%
Pretax Income -$3.830M -$3.550M -$240.0K
YoY Change 681.63% 1379.17% -33.33%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.825M -$3.547M -$239.9K
YoY Change 687.27% 1378.73% -33.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$633.1K -$588.7K -$210.5K
COMMON SHARES
Basic Shares Outstanding 6.100M shares 6.100M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.18M $16.05M $1.050M
YoY Change -48.69% 1428.57%
Cash & Equivalents $12.18M $16.05M $1.050M
Short-Term Investments
Other Short-Term Assets $1.130M $890.0K $0.00
YoY Change
Inventory
Prepaid Expenses $1.132M $888.9K
Receivables
Other Receivables
Total Short-Term Assets $13.31M $16.93M $1.050M
YoY Change -43.94% 1512.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $82.55K $88.46K $740.0K
YoY Change -88.05%
Total Long-Term Assets $82.55K $88.46K $740.0K
YoY Change -88.05%
TOTAL ASSETS
Total Short-Term Assets $13.31M $16.93M $1.050M
Total Long-Term Assets $82.55K $88.46K $740.0K
Total Assets $13.39M $17.02M $1.790M
YoY Change -43.59% 851.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.050M $1.300M $600.0K
YoY Change -11.02% 116.67%
Accrued Expenses $640.0K $540.0K $190.0K
YoY Change 64.1% 184.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $700.0K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $1.685M $1.837M $1.710M
YoY Change -36.08% 7.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.240M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $10.00K $20.00K
YoY Change
Total Long-Term Liabilities $10.00K $20.00K $2.240M
YoY Change -99.47% -99.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.685M $1.837M $1.710M
Total Long-Term Liabilities $10.00K $20.00K $2.240M
Total Liabilities $1.700M $1.854M $3.950M
YoY Change -62.35% -53.07%
SHAREHOLDERS EQUITY
Retained Earnings -$33.02M -$29.19M
YoY Change
Common Stock $611.00 $610.00
YoY Change 5.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.69M $15.17M -$2.160M
YoY Change
Total Liabilities & Shareholders Equity $13.39M $17.02M $1.790M
YoY Change -43.59% 851.01%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$3.825M -$3.547M -$239.9K
YoY Change 687.27% 1378.73% -33.12%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.910M -$3.070M -$430.0K
YoY Change 1348.15% 613.95% 22.86%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K -2.720M -190.0K
YoY Change -99.83% 1331.58%
NET CHANGE
Cash From Operating Activities -3.910M -3.070M -430.0K
Cash From Investing Activities
Cash From Financing Activities 40.00K -2.720M -190.0K
Net Change In Cash -3.870M -5.790M -620.0K
YoY Change -117.06% 833.87% 77.14%
FREE CASH FLOW
Cash From Operating Activities -$3.910M -$3.070M -$430.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1837015
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6099547 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
610
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29193992
CY2014Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1299561
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6099547 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1050439
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6099547 shares
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
15169257
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17023161
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44362639
CY2014Q2 us-gaap Liabilities
Liabilities
1853904
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
537454
CY2014Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
16889
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16045799
CY2014Q2 us-gaap Assets
Assets
17023161
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2900000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
88459
CY2014Q2 us-gaap Assets Current
AssetsCurrent
16934702
CY2014Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
888903
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116013
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6096752 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6096752 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2284906
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
610
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22691468
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1442592
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
284915
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
21183261
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1511461
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24986458
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43874119
CY2013Q4 us-gaap Liabilities
Liabilities
3803197
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
557399
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6830
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24196691
CY2013Q4 us-gaap Assets
Assets
24986458
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
555505
CY2013Q4 us-gaap Assets Current
AssetsCurrent
24430953
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234262
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-876324
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
49000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1135250 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
107500 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2584252 shares
us-gaap Interest Income Other
InterestIncomeOther
2221
us-gaap Operating Income Loss
OperatingIncomeLoss
-535454
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-198409
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
189250
us-gaap Net Income Loss
NetIncomeLoss
-733863
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
241827
us-gaap Other Noncash Expense
OtherNoncashExpense
11630
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
2000000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
934426
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
121000
us-gaap Interest Paid
InterestPaid
60250
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
742613
us-gaap Operating Expenses
OperatingExpenses
535454
us-gaap Interest Expense Other
InterestExpenseOther
79630
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1810750
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
293627
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
461270
us-gaap Share Based Compensation
ShareBasedCompensation
6252
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
83125 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001403708
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma Inc
dei Trading Symbol
TradingSymbol
EVOK
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M11D
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5068207
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6015310 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
790112 shares
us-gaap Interest Income Other
InterestIncomeOther
7270
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
82685
us-gaap Operating Income Loss
OperatingIncomeLoss
-6414460
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-88064
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
3000000
us-gaap Net Income Loss
NetIncomeLoss
-6502524
us-gaap Interest Paid
InterestPaid
58790
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-10059
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
107133
us-gaap Operating Expenses
OperatingExpenses
6414460
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4727093
us-gaap Other Noncash Expense
OtherNoncashExpense
48170
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8150892
us-gaap Interest Expense Other
InterestExpenseOther
95334
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3082685
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1687367
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
994701
us-gaap Share Based Compensation
ShareBasedCompensation
488520
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1137125 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
105625 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2584252 shares
CY2013Q2 us-gaap Interest Income Other
InterestIncomeOther
868
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-203424
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-36447
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-239871
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3126
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6027672 shares
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
616888
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
265210
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
203424
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
130846
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3000
CY2013Q2 us-gaap Interest Expense Other
InterestExpenseOther
40315
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
72578
CY2014Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
71875 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
788771 shares
CY2014Q2 us-gaap Interest Income Other
InterestIncomeOther
3215
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3491865
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-55175
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3547040
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
3491865
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2874977
CY2014Q2 us-gaap Interest Expense Other
InterestExpenseOther
58390

Files In Submission

Name View Source Status
0001193125-14-308400-index-headers.html Edgar Link pending
0001193125-14-308400-index.html Edgar Link pending
0001193125-14-308400.txt Edgar Link pending
0001193125-14-308400-xbrl.zip Edgar Link pending
d745367d10q.htm Edgar Link pending
d745367dex311.htm Edgar Link pending
d745367dex312.htm Edgar Link pending
d745367dex321.htm Edgar Link pending
d745367dex322.htm Edgar Link pending
evok-20140630.xml Edgar Link completed
evok-20140630.xsd Edgar Link pending
evok-20140630_cal.xml Edgar Link unprocessable
evok-20140630_def.xml Edgar Link unprocessable
evok-20140630_lab.xml Edgar Link unprocessable
evok-20140630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending